Neuronal aerobic glycolysis exacerbates synapse loss in aging mice

Copyright © 2023 Elsevier Inc. All rights reserved..

Brain consumes nearly 20% supply of energy from glucose metabolism by oxidative phosphorylation and aerobic glycolysis. Less active state of glycolytic enzymes results in a limited capacity of glycolysis in the neurons of adult brain. Here we identified that Warburg effect is enhanced in hippocampal neurons during aging. As hippocampal neurons age, lactate levels progressively increase. Notably, we observed upregulated protein levels of PFKFB3 in the hippocampus of 20-month-old mice compared to young mice, and this higher PFKFB3 expression correlated with declining memory performance in aging mice. Remarkably, in aging mice, knocking down Pfkfb3 in hippocampal neurons rescued cognitive decline and synapse loss. Conversely, Pfkfb3 overexpression in hippocampal neurons led to cognitive impairment and synapse elimination, associated with heightened glycolysis. In vitro experiments with cultured primary neurons confirmed that Pfkfb3 overexpression increased glycolysis and that glycolytic inhibition could prevent apoptotic competency in neurons. These findings underscore that glycolysis in hippocampal neurons could potentially be targeted as a therapeutic avenue to mitigate cognitive decline and preserve synaptic integrity during aging.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:371

Enthalten in:

Experimental neurology - 371(2024) vom: 17. Jan., Seite 114590

Sprache:

Englisch

Beteiligte Personen:

Zhou, Wenhui [VerfasserIn]
Yang, Xingyue [VerfasserIn]
Wang, Huixia [VerfasserIn]
Yao, Wenjuan [VerfasserIn]
Chu, Dandan [VerfasserIn]
Wu, Feng [VerfasserIn]

Links:

Volltext

Themen:

Aerobic glycolysis
Aging
Cognitive decline
EC 2.7.1.105
Journal Article
PFKFB3
Phosphofructokinase-2
Research Support, Non-U.S. Gov't
Synapse loss

Anmerkungen:

Date Completed 16.12.2023

Date Revised 22.01.2024

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.expneurol.2023.114590

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM363990402